Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases
- PMID: 30712197
- DOI: 10.1007/s10549-019-05148-5
Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases
Abstract
Objectives: Human epidermal growth factor receptor 2 (HER2, ERBB2) is a valuable prognostic and predictive biomarker in breast cancer. Accurate assessment of HER2 status is essential in selecting the patients with invasive breast cancer who will likely response to HER2-targeted therapies. Some major modifications in the diagnostic recommendation for fluorescence in situ hybridization (FISH) have been made in the updated 2018 American Society of Clinical Oncology (ASCO)/College of American Pathologist (CAP) guideline. According to the revised guideline, concomitant IHC assays are required to arrive at the most accurate HER2 status designation after HER2 FISH equivocal results; however, little is known about its influence on the clinical practice of pathologist. The purpose of this study was to evaluate the impact of the revised 2018 ASCO/CAP guidelines on the HER2 status designation.
Methods: We retrospectively reviewed the HER2 FISH testing results from 2233 cases of invasive breast cancer between January 2014 and December 2017. Concomitant immunohistochemistry (IHC) were performed on the same tissue blocks that were used for the FISH testing.
Results: Compared to the 2013 guidelines, the HER2 status in 183 (8.2%) cases were re-defined when reassessed by the 2018 guidelines. Among these 183 cases, 175 equivocal cases according to the 2013 guideline were re-defined as HER2 negative (n = 173) or HER2 positive (n = 2). Eight previously classified as HER2 positive cases were converted to negative in the 2018 scheme, all of which were with HER2 IHC scores of 1+ or 2+. The number of cases in the negative category was 1705 according to the 2018 guidelines as opposed to 1524 by the 2013 guidelines.
Conclusions: The updated 2018 ASCO/CAP guidelines eliminated the FISH equivocal category, which can be attributed to reflex HER2 IHC, and partly ease the dilemma for clinical practice. Reflex IHC for FISH equivocal cases is of prime importance; furthermore, HER2 FISH results were converted from positivity to negativity based on the concomitant IHC results in a small percentage of cases. In all, implementation of the 2018 ASCO/CAP guidelines provides much clearer instructions and recommendations for the HER2 status designation, and thus reduces the risk of misdiagnosis.
Keywords: ASCO/CAP guidelines; Breast cancer; Fluorescence in situ hybridization; HER2; Immunohistochemistry.
Similar articles
-
Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.Breast Cancer Res Treat. 2017 Nov;166(1):77-84. doi: 10.1007/s10549-017-4397-z. Epub 2017 Jul 15. Breast Cancer Res Treat. 2017. PMID: 28712009
-
Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.Breast Cancer Res Treat. 2016 Jun;157(3):405-11. doi: 10.1007/s10549-016-3824-x. Epub 2016 May 14. Breast Cancer Res Treat. 2016. PMID: 27180259
-
HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.Breast Cancer Res Treat. 2016 Feb;155(3):457-62. doi: 10.1007/s10549-016-3717-z. Epub 2016 Feb 19. Breast Cancer Res Treat. 2016. PMID: 26895325
-
Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.PLoS One. 2020 Nov 12;15(11):e0241775. doi: 10.1371/journal.pone.0241775. eCollection 2020. PLoS One. 2020. PMID: 33180796 Free PMC article. Review.
-
American Society of Clinical Oncology/College of American Pathologists 2018 Focused Update of Breast Cancer HER2 FISH Testing GuidelinesResults From a National Reference Laboratory.Am J Clin Pathol. 2019 Sep 9;152(4):479-485. doi: 10.1093/ajcp/aqz061. Am J Clin Pathol. 2019. PMID: 31172196 Review.
Cited by
-
Indian Data on HER2 Fluorescence In Situ Hybridization in Invasive Breast Cancer with Immunohistochemically Equivocal Results As Per 2018 ASCO/CAP Guidelines.South Asian J Cancer. 2022 Aug 23;11(4):281-286. doi: 10.1055/s-0042-1751052. eCollection 2022 Oct. South Asian J Cancer. 2022. PMID: 36756105 Free PMC article.
-
A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China.BMC Cancer. 2023 Jan 25;23(1):84. doi: 10.1186/s12885-023-10531-z. BMC Cancer. 2023. PMID: 36698078 Free PMC article.
-
A Soft Label Deep Learning to Assist Breast Cancer Target Therapy and Thyroid Cancer Diagnosis.Cancers (Basel). 2022 Oct 28;14(21):5312. doi: 10.3390/cancers14215312. Cancers (Basel). 2022. PMID: 36358732 Free PMC article.
-
Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer.Cancers (Basel). 2022 Aug 17;14(16):3973. doi: 10.3390/cancers14163973. Cancers (Basel). 2022. PMID: 36010967 Free PMC article.
-
Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients.Front Oncol. 2021 Nov 11;11:774088. doi: 10.3389/fonc.2021.774088. eCollection 2021. Front Oncol. 2021. PMID: 34858854 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous